Clarivate Management
Management Kriterienprüfungen 2/4
Clarivate CEO ist Matti Shem Tov , ernannt in Aug 2024, hat eine Amtszeit von 1.75 Jahren. Die jährliche Gesamtvergütung beträgt $8.35M , bestehend aus 10.8% Gehalt und 89.2% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.42% der Aktien des Unternehmens, im Wert von $7.42M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3 Jahre bzw. 4.1 Jahre.
Wichtige Informationen
Matti Shem Tov
Geschäftsführender
US$8.4m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 10.78% |
| Amtszeit als Geschäftsführer | 1.8yrs |
| Eigentum des Geschäftsführers | 0.4% |
| Durchschnittliche Amtszeit des Managements | 3yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 4.1yrs |
Jüngste Management Updates
Recent updates
CLVT: Free Cash Flow And Portfolio Simplification May Support Future Upside Potential
The Analyst Price Target for Clarivate has been reduced by about $1, with analysts pointing to AI disintermediation risk and uncertainty around the planned Life Sciences and Healthcare unit sale as key reasons for the reset. Analyst Commentary Recent research points to a more cautious stance on Clarivate, with several banks trimming price targets while keeping a range of ratings from Underweight to Buy.
CLVT: Fair Value View Weighs AI Disruption Against Portfolio Reshaping Risks
Analyst price targets on Clarivate have reset sharply lower into a $2.40 to $6 range, with cuts of up to about $2 to $2.60 as analysts factor in AI disruption risks and uncertainty around the planned Life Sciences and Healthcare segment sale. Analyst Commentary Recent research updates on Clarivate highlight a cautious tilt, with several bearish analysts resetting expectations lower despite references to solid free cash flow metrics and outlined growth targets.CLVT: Fair Value View Balances AI Competition With Portfolio Execution Risks
Clarivate's analyst price targets have moved lower toward a new implied fair value near $2.40 per share, as analysts factor in slower revenue growth assumptions, lower profit margin expectations, AI related competitive risks, and execution risk around the planned Life Sciences and Healthcare unit sale. Analyst Commentary Recent Street research on Clarivate has tilted more cautious, with several bearish analysts cutting price targets and, in one case, downgrading the stock.
CLVT: Value Creation Plan Execution Will Drive Upside Despite AI Headwinds
Our analyst price target for Clarivate has moved down from $7.00 to $6.00 as analysts trim their targets across the Street. They cite AI related competitive pressures, the execution risk around a potential Life Sciences and Healthcare sale, and a longer timeline for the company’s Value Creation Plan to play out.CLVT: Extended Plan Execution Will Unlock Value Despite Rising AI Competition
Analysts have trimmed their $4.20 price target on Clarivate to $3.60, reflecting concerns that rising competition from AI-focused rivals, limits on pricing power, and a longer timeline for the company's "Value Creation Plan" temper expectations for organic revenue growth and profitability. Analyst Commentary Goldman Sachs cut its rating on Clarivate to Neutral from Buy and reduced its price target to $3.60 from $4.20, signaling a more cautious stance on the shares.CLVT: Extended Value Creation Plan Timeline May Support Future Upside Potential
Analysts have trimmed their price target on Clarivate to about US$3.60 from roughly US$4.20, citing a longer timeline for the company's "Value Creation Plan" to influence organic revenue growth, as well as concerns about pressure from AI driven competitors and limited pricing power. Analyst Commentary Bullish Takeaways Bullish analysts still see some value support around the revised US$3.60 target, suggesting expectations have been reset to reflect slower organic growth execution.Clarivate Plc's (NYSE:CLVT) 35% Dip In Price Shows Sentiment Is Matching Revenues
Feb 04
CLVT: Extended Plan And AI Competition Will Shape Long-Term Execution Outlook
Analysts have trimmed their price target on Clarivate to $3.60 from $4.20, citing expectations for a longer timeline for the Value Creation Plan to influence organic revenue growth, as well as concerns around competition from AI focused peers and limited pricing power. Analyst Commentary Recent Street research reflects a more cautious stance on Clarivate, with at least one major firm reducing its rating and target price as expectations temper around execution of the Value Creation Plan and the pace of organic revenue growth.CLVT: Extended Value Creation Timeline Will Confront Intensifying AI Competition
Analysts have trimmed their fair value estimate for Clarivate from US$3.75 to US$3.00, citing a lower Street price target and expectations that the company’s "Value Creation Plan" and efforts to improve organic revenue growth may take longer to show results in the face of rising AI driven competition and limited pricing power. Analyst Commentary Recent Street commentary has turned more cautious on Clarivate, with some price targets cut and ratings pulled back as expectations around the "Value Creation Plan" are reset to a longer timetable.CLVT: Share Repurchases Will Support Future Earnings Upside
Analysts have trimmed their price target on Clarivate by approximately $0.25. This reflects slightly higher perceived risk via a modestly increased discount rate and a lower future earnings multiple, while leaving their long term growth and profitability assumptions essentially unchanged.CLVT: Share Buybacks And Raised Guidance Will Support Future Performance
Analysts have slightly lowered their price target on Clarivate to reflect modestly reduced discount rate assumptions and a marginally lower future price-to-earnings multiple, while keeping their fair value estimate effectively unchanged at approximately $4.93 per share. What's in the News Clarivate completed a share repurchase of 34,823,885 shares, representing 5.11% of outstanding shares, for a total of $149.47 million under its December 16, 2024 buyback authorization (Key Developments).CLVT: Strong Market Share Will Support Future Performance Despite AI Risk
Analysts have slightly raised their price target for Clarivate to nearly $5 per share. They cite the firm’s solid market position but note ongoing risks from budget constraints, AI competition, and leverage concerns.CLVT: Market Position And AI Developments Will Drive Performance Ahead
Analysts have lowered Clarivate's price target from approximately $5.14 to $4.93 per share. They cite concerns over budget constraints in key sectors, potential risks from artificial intelligence, and the company’s elevated leverage, despite its strong market position.Clarivate: Downgrade To Hold As The Recovery Momentum Is Not Showing Up
Nov 01These 4 Measures Indicate That Clarivate (NYSE:CLVT) Is Using Debt Extensively
Sep 16Earnings Update: Clarivate Plc (NYSE:CLVT) Just Reported Its Second-Quarter Results And Analysts Are Updating Their Forecasts
Aug 02Is There An Opportunity With Clarivate Plc's (NYSE:CLVT) 32% Undervaluation?
Jul 26At US$4.40, Is Clarivate Plc (NYSE:CLVT) Worth Looking At Closely?
Jul 08Subscription Model And AI Integration Will Drive Operational Efficiency
Transitioning to a subscription-based model and AI innovation enhances revenue stability and competitive edge, supporting growth and improving net margins.Optimistic Investors Push Clarivate Plc (NYSE:CLVT) Shares Up 27% But Growth Is Lacking
May 04Clarivate Plc (NYSE:CLVT) Shares Could Be 33% Below Their Intrinsic Value Estimate
Apr 23Should You Investigate Clarivate Plc (NYSE:CLVT) At US$3.37?
Apr 08Some Confidence Is Lacking In Clarivate Plc's (NYSE:CLVT) P/S
Mar 03Clarivate: Another Weak Year Ahead
Feb 23Is Clarivate (NYSE:CLVT) Using Too Much Debt?
Jan 26Are Investors Undervaluing Clarivate Plc (NYSE:CLVT) By 27%?
Jan 08Clarivate: Clearing The Decks
Dec 26Is Clarivate Plc (NYSE:CLVT) Potentially Undervalued?
Dec 16Clarivate: Downgrade To Hold As Growth May Take A Long Time To Recover
Nov 08Some Confidence Is Lacking In Clarivate Plc (NYSE:CLVT) As Shares Slide 26%
Nov 07Here's Why Clarivate (NYSE:CLVT) Has A Meaningful Debt Burden
Sep 27Clarivate Plc (NYSE:CLVT) Stock Rockets 31% As Investors Are Less Pessimistic Than Expected
Sep 06Is Clarivate Plc (NYSE:CLVT) Trading At A 43% Discount?
Aug 29Clarivate: Attractive Upside Even With Conservative Assumptions
Aug 09Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$137m |
| Dec 31 2025 | US$8m | US$900k | -US$201m |
| Sep 30 2025 | n/a | n/a | -US$396m |
| Jun 30 2025 | n/a | n/a | -US$433m |
| Mar 31 2025 | n/a | n/a | -US$678m |
| Dec 31 2024 | US$5m | US$353k | -US$668m |
Vergütung im Vergleich zum Markt: MattiDie Gesamtvergütung ($USD8.35M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt US ($USD5.37M).
Entschädigung vs. Einkommen: MattiDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.
Geschäftsführer
Matti Shem Tov (64 yo)
1.8yrs
Amtszeit
US$8,350,984
Vergütung
Mr. Matitiahu Shem Tov, also known as Matti, is Chief Executive Officer & Director of Clarivate Plc from August 9, 2024. Mr. Shem Tov serves as a Senior Advisor at Lone View Capital Management, L.P. He joi...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$8.35m | 0.42% $ 7.4m | |
| Executive VP & CFO | 4.4yrs | US$4.20m | 0.18% $ 3.2m | |
| President of Academia & Government | 3.1yrs | US$3.47m | 0.072% $ 1.3m | |
| President of Life Sciences & Healthcare | 3yrs | US$3.40m | 0.16% $ 2.8m | |
| President of Intellectual Property | less than a year | US$3.02m | 0.16% $ 2.9m | |
| Senior VP of Finance & Chief Accounting Officer | 3.9yrs | keine Daten | 0.11% $ 2.0m | |
| Executive VP & Chief Information Officer | 4.2yrs | keine Daten | 0.13% $ 2.3m | |
| Head of Investor Relations | no data | keine Daten | keine Daten | |
| Senior VP & General Counsel | 1.3yrs | keine Daten | keine Daten | |
| Senior Vice President of Communications & Brand | no data | keine Daten | keine Daten | |
| Senior VP & Head of People | 1.2yrs | keine Daten | keine Daten | |
| Global Head of Life Sciences Consulting Services | 6.8yrs | keine Daten | keine Daten |
3.0yrs
Durchschnittliche Betriebszugehörigkeit
52yo
Durchschnittliches Alter
Erfahrenes Management: CLVTDas Führungsteam des Unternehmens gilt als erfahren (3 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO & Director | 1.8yrs | US$8.35m | 0.42% $ 7.4m | |
| Independent Director | 7yrs | keine Daten | keine Daten | |
| Independent Non-Executive Chairman of the Board | 4.4yrs | US$370.00k | 0.064% $ 1.1m | |
| Independent Director | 5.6yrs | keine Daten | keine Daten | |
| Independent Director | 6yrs | US$280.00k | 0.045% $ 809.1k | |
| Independent Director | less than a year | US$168.85k | 0.17% $ 3.1m | |
| Independent Director | 3.8yrs | US$270.00k | 0.0097% $ 173.9k | |
| Independent Director | 5.6yrs | keine Daten | keine Daten | |
| Independent Director | 3yrs | US$250.00k | 0.012% $ 214.9k | |
| Independent Director | 2yrs | US$250.00k | 0.0019% $ 33.3k |
4.1yrs
Durchschnittliche Betriebszugehörigkeit
56yo
Durchschnittliches Alter
Erfahrener Vorstand: CLVTDie Vorstandsmitglieder gelten als erfahren (4.1 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/03 06:27 |
| Aktienkurs zum Tagesende | 2026/05/01 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Clarivate Plc wird von 13 Analysten beobachtet. 9 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Manav Patnaik | Barclays |
| Heather Balsky | BofA Global Research |
| Zachary Cummins | B. Riley Securities, Inc. |